Drug intelligence / Profile preview

GSK3844766A + AS01E

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

**GSK3844766A + AS01E** is a combination vaccine candidate for the prevention of moderate-to-severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in older adults[3][5][7]. The drug consists of the RSVPreF3 recombinant antigen (GSK3844766A) formulated with GSK’s proprietary AS01E adjuvant system to enhance the immune response in this population, which typically exhibits weaker immunity to vaccination. The vaccine is administered intramuscularly and has undergone Phase I/II clinical evaluation. Immunization stimulates robust neutralizing antibody and cellular responses against RSV, with AS01E boosting both magnitude and duration of immunity[3][4][5][7].

Other names
RSVPreF3 OA investigational vaccineRSVPreF-3 OA investigational vaccineRSVPreF 3 OA investigational vaccine
02

Targets

RSV F (Respiratory syncytial virus fusion protein)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on GSK3844766A + AS01E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3844766A + AS01E.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call